EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Metabolic reprogramming by histone deacetylase inhibition preferentially targets NRF2-activated tumors

Dimitris Karagiannis, Warren Wu, Albert Li, Makiko Hayashi, Xiao Chen, Michaela Yip, Vaibhav Mangipudy, Xinjing Xu, Francisco J Sánchez-Rivera, Yadira M Soto-Feliciano, Jiangbin Ye, Thales Papagiannakopoulos und 1 weitere

Cell Reports · 2024

DOI: 10.1016/j.celrep.2023.113629 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2024. Verfasst von Dimitris Karagiannis und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Neoplasms, NF-E2-Related Factor 2. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsNF-E2-Related Factor 2AnimalsHumansMiceChromatinHistone Deacetylase InhibitorsHistone DeacetylasesMetabolic Reprogramming

Stichwörter der Autor:innen

CP: CancerHDAC inhibitorsNRF2 pathwaycancer epigeneticscancer metabolismcancer targeted therapyepigenetic reprogramminglung cancer

Substanzen

ChromatinHistone Deacetylase InhibitorsHistone DeacetylasesNF-E2-Related Factor 2NFE2L2 protein, human

Autor:innen und Institutionen

  • Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Department of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
  • Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
  • Department of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; Laura and Isaac Perlmutter NYU Cancer Center, New York University Grossman School of Medicine, New York, NY 10016, USA.
  • Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.…

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • NIDDK NIH HHS
  • NIH HHS
  • NIDCR NIH HHS

Zitieren

APA

Karagiannis, D., Wu, W., Li, A., Hayashi, M., Chen, X., Yip, M., Mangipudy, V., Xu, X., Sánchez-Rivera, F. J., Soto-Feliciano, Y. M., Ye, J., Papagiannakopoulos, T., & Lu, C. (2024). Metabolic reprogramming by histone deacetylase inhibition preferentially targets NRF2-activated tumors. Cell Reports. https://doi.org/10.1016/j.celrep.2023.113629

Vancouver

Karagiannis D, Wu W, Li A, Hayashi M, Chen X, Yip M, et al. Metabolic reprogramming by histone deacetylase inhibition preferentially targets NRF2-activated tumors. Cell Reports. 2024. doi:10.1016/j.celrep.2023.113629

BibTeX
@article{Karagiannis2024,
  author = {Karagiannis, Dimitris and Wu, Warren and Li, Albert and Hayashi, Makiko and Chen, Xiao and Yip, Michaela and Mangipudy, Vaibhav and Xu, Xinjing and Sánchez-Rivera, Francisco J and Soto-Feliciano, Yadira M and Ye, Jiangbin and Papagiannakopoulos, Thales and Lu, Chao},
  title = {Metabolic reprogramming by histone deacetylase inhibition preferentially targets NRF2-activated tumors},
  journal = {Cell Reports},
  year = {2024},
  doi = {10.1016/j.celrep.2023.113629}
}
Kostenlos starten →